| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 76, 757-762, Copyright © 1993 by Endocrine Society
ARTICLES |
T Mune, H Katakami, Y Kato, K Yasuda, S Matsukura and K Miura
Third Department of Internal Medicine, Gifu University School of Medicine, Japan.
We studied the relation between calcium metabolism and serum PTH- related protein (PTHrP)-like immunoreactivity (PRP-LI) in 12 patients with benign pheochromocytoma, 10 of whom had not received any medication before admission. Basal serum PRP-LI levels were elevated in 7 of these 10 untreated patients. After tumor resection, serum PRP-LI became undetectable in all 10 patients examined. Serum calcium decreased (P < 0.01), and serum phosphorus increased significantly (P < 0.05) after tumor resection. Serum PTH increased in 5 of 7 patients postoperatively. alpha-Adrenoceptor-blocking agents given as preoperative treatment (n = 6) decreased elevated PRP-LI levels in 5 patients, had no effect in the remaining patient with undetectable levels, and tended to decrease serum calcium levels that were normal in 5 of 6 patients and elevated in 1, while serum phosphorus levels showed reciprocal changes. In the remaining 2 patients who had received alpha- adrenoceptor-blocking agents before admission, serum PRP-LI was undetectable. Tissue PRP-LI concentrations were high in all resected tumors (n = 8). Western blot analysis of tumor extracts showed multiple bands at about 14, 16, 21, 27, and 34 kilodaltons, which differed among tumors. Northern blot analysis of PTHrP mRNA (n = 5) and immunohistochemistry (n = 5) showed positive findings. These findings suggest that PTHrP is synthesized in pheochromocytoma and released into the general circulation, probably via an alpha-adrenergic mechanism, and that changes in serum PRP-LI levels are fairly positively associated with those in serum calcium levels in patients with pheochromocytoma.
This article has been cited by other articles:
![]() |
R. Herring and K. Laji Humoral hypercalcaemia of benignancy. A case report QJM, April 1, 2008; 101(4): 329 - 330. [Full Text] [PDF] |
||||
![]() |
T. P. Jacobs and J. P. Bilezikian Rare Causes of Hypercalcemia J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6316 - 6322. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Smith, A. L. J. Slappy, T. P. Fox, and J. S. Scolapio Pheochromocytoma Producing Vasoactive Intestinal Peptide Mayo Clin. Proc., January 1, 2002; 77(1): 97 - 100. [Abstract] [PDF] |
||||
![]() |
G. Mazzocchi, F. Aragona, L. K. Malendowicz, and G. G. Nussdorfer PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells Am J Physiol Endocrinol Metab, February 1, 2001; 280(2): E209 - E213. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |